Lemborexant

莱博雷生

Report date: 2026/05/09 20:00:18
NME

Base Information

Drug NameLemborexant
Drug Alias NameLemborexantum仑布雷生DAYVIGOTMDayvigoDAYVIGO +[9] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionOrexin receptor type 1 antagonistsOrexin receptor type 2 antagonists
TargetsOrexin receptor type 1Orexin receptor type 2
Therapy Area/IndicationsDepressive Disorder, MajorMental DisordersSleep +[18] 
Global Approved IndicationsSleep Initiation and Maintenance Disorders
Approved Indications in ChinaSleep Initiation and Maintenance Disorders
Original Approved Country/TerritoryUnited States
Original Approved Date2019/12/20
Country/TerritoryCanadaUnited StatesTaiwan +[21] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesEisai Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesWoolcock Institute Of Medical ResearchUniversity of TorontoToronto Metropolitan University +[16] 
Inactive CompaniesCentre Integre Universitaire De Sante Et Services Sociaux Du Nord De L'Ile De MontrealPurdue Pharma Lp
Active IndicationsDepressive Disorder, MajorSleepOpioid-Related Disorders +[14] 
Inactive IndicationsMental DisordersRenal InsufficiencySleep Disorders, Circadian Rhythm +[4] 

Other Information

ATC CodeN05C
Related LinksWikipediaDrugBankKEGG